How We Can Help
Healthtech and Biotech M&A
The healthcare tech and biotech industries shifted fundamentally during the pandemic. Enthusiasm for dealmaking continues to be a growth area.
Tech M&A Outlook
After a pullback in tech M&A in 2022, and with IPO markets sluggish, dealmakers expect an uptick in M&A activity in 2023.
Cross-Border Dealmaking
The M&A landscape has shifted this year to take account of more strategic concerns. Companies are focused on supply chain disruption, inflation and geopolitical unrest, creating interesting opportunities for buyers.
